SP1 and prostate cancer: In summary, our data indicate that the Sp1/Sp3/FLIP signature in combination with Gleason grade is predictive of recurrence of prostate cancer and that its clinical application might avoid unnecessary aggressive interventions, thus improving quality of life and reducing healthcare related expenses.